CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Capecitabinedrug
Likely dose
Capecitabine 1,250 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00717197
NCT00717197Phase 2Completed
CompareCT.gov

Pilot Study to Determine Therapeutic Response of Oral Capecitabine (Xeloda) in Recurrent High Grade Gliomas (HGGs) by Establishing the Radiographic Response Rate Using Modified Macdonald Criteria

University of Florida·interventional·Posted Jul 17, 2008·Updated Jul 2, 2013

In Brief

A Phase 2 clinical trial evaluating Capecitabine for Malignant Glioma. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if capecitabine is effective in the treatment of high grade gliomas that have returned after completing treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Glioma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 17, 2008
Enrollment StartJul 1, 2008
Primary CompletionMar 1, 2012
Study CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 18.0 years ago

Interventions

Capecitabinedrug

1,000-1,250 mg/m2 taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.